By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Addex Therapeutics 

12, Chemin Des Aulx
1228 Plan-les-Ouates
Geneva      Switzerland
Phone: 41-22-884-1555 Fax: 41-22-884-1556




Company News
Addex Therapeutics (ADXN.SW) Dipraglurant Dosed In First Subject In Receptor Occupancy Study In Collaboration With Johns Hopkins University And With Funding From The Michael J. Fox Foundation 7/22/2015 10:50:44 AM
Addex Therapeutics (ADXN.SW) Shareholders Appoint Raymond Hill And Tim Dyer To The Board Of Directors And Approve All Board Proposals At Annual General Meeting 6/12/2015 8:54:16 AM
Addex Therapeutics (ADXN.SW) Identifies New Potential Use Of mGlu7 Receptor NAMs To Treat Stress-Induced Visceral Pain 6/3/2015 7:45:21 AM
Addex Therapeutics (ADXN.SW) And Prof. Pisani Present Dipraglurant Data In Rare Inherited Forms Of Dystonia 5/29/2015 8:58:53 AM
Addex Therapeutics (ADXN.SW) Annual General Meeting Scheduled For 11 June 2015 5/27/2015 10:55:28 AM
Addex Therapeutics (ADXN.SW) Enters Collaboration With Prof. Pisani To Explore The Therapeutic Use Of Dipraglurant In The Treatment Of Rare Inherited Forms Of Dystonia 5/7/2015 8:38:33 AM
Addex Therapeutics (ADXN.SW) Reports 2014 Financial Results 4/30/2015 8:47:35 AM
Addex Therapeutics (ADXN.SW) Raises CHF2.8 million In A Private Placement And Extends Cash Runway Through 2017 3/9/2015 8:58:10 AM
Addex Therapeutics (ADXN.SW) Initiates Dipraglurant Receptor Occupancy Clinical Study In Collaboration With Johns Hopkins University With Funding From The Michael J. Fox Foundation 2/23/2015 10:29:31 AM
Addex Therapeutics (ADXN.SW) mGluR2 NAM Demonstrates Protection In Preclinical Model Of Ischemic Neuronal Death 2/19/2015 11:17:08 AM